GlassScriptPhysician profile
Mohit Dugar
NPI 1679734016
$4,126.59
in general payments reported to CMS, 2019-2025
25 companies · $726 in 2025
The $726 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $593 · 2020: $88.71 · 2021: $508 · 2022: $804 · 2023: $741 · 2024: $666 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,133.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $534.35 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $528.10 | 2021-2025 | Tremfya, Remicade, Simponi |
| Lilly USA, LLC | $504.69 | 2021-2025 | Taltz |
| Novartis Pharmaceuticals Corporation | $482.69 | 2019-2025 | |
| Amgen INC. | $376.90 | 2019-2025 | Evenity, Prolia, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.62 | 2021-2023 | Ofev, Cyltezo |
| Abbvie INC. | $206.95 | 2021-2025 | Rinvoq |
| Glaxosmithkline, LLC. | $191.04 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $154.27 | 2023-2025 | Acthar |
| Janssen Pharmaceuticals, INC | $132.29 | 2025 | Tremfya |
| Pfizer INC. | $126.09 | 2021 | |
| Horizon Therapeutics Plc | $124.01 | 2019 | |
| Scilex Pharmaceuticals INC. | $114.14 | 2024-2025 | |
| Celgene Corporation | $53.84 | 2019 | |
| Alexion Pharmaceuticals, INC. | $42.73 | 2023-2025 | Strensiq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $38.48 | 2022 | |
| Aurinia Pharma U.S., INC. | $35.98 | 2021-2022 | |
| Exact Sciences Corporation | $31.95 | 2025 | Cologuard Collection Kit |
| Mylan Institutional INC. | $28.47 | 2023 | Fulphila |
| Terumo Medical Corporation | $26.79 | 2019 | |
| Ani Pharmaceuticals, INC. | $24.16 | 2025 | Purified Cortrophin Gel |
| Oxford Immunotec USA INC | $22.29 | 2022 | |
| Invivyd INC | $19.75 | 2025 | Pemgarda |
| Sandoz INC. | $18.24 | 2023 | Hyrimoz |
| Hikma Pharmaceuticals USA | $12.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohit Dugar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.